DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

Information source: Scott and White Hospital & Clinic
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heavy Menstrual Bleeding; Menorrhagia; Hypermenorrhea

Intervention: Norethindrone acetate pretreatment (Drug); No pretreatment (Other)

Phase: Phase 4

Status: Recruiting

Sponsored by: Scott and White Hospital & Clinic

Official(s) and/or principal investigator(s):
Patricia J Sulak, MD, Principal Investigator, Affiliation: Scott and White Hospital & Clinic

Overall contact:
Wendy M White, CCRP, Phone: 254-724-8301, Email: wewhite@swmail.sw.org

Summary

Problematic uterine bleeding after the insertion of the LNG IUS is a well documented side effect. The levonorgestrel intrauterine system (LNG IUS) was approved for treatment of heavy menstrual bleeding (HMB) by the FDA in October 2009. To reduce the incidence and severity of post-insertional uterine bleeding, pretreatment with norethindrone acetate may effectively slough the endometrium prior to insertion of the LNG IUS.

Clinical Details

Official title: Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Total number of bleeding days

Secondary outcome: Menorrhagia Questionnaire

Detailed description: This study will examine whether or not pretreatment with oral norethindrone acetate prior to the insertion of a hormonal intrauterine device will affect post-insertional uterine bleeding. The subjects enrolling in the study will have documented heavy menstrual bleeding (HMB) and desire the levonorgestrel intrauterine system (LNG IUS) (Mirena®, Bayer, Inc. Pittsburgh, PA) for symptomatic relief. HMB for this study is defined as heavy bleeding at regular intervals at least 20-40 days apart. Subjects will be randomized to one of two groups. One group will receive norethindrone acetate for two consecutive months prior to LNG IUS insertion while the other group will proceed with direct insertion of the LNG IUS with no hormonal pre-treatment. Subjects will be followed for a period of 180 days post LNG IUS insertion. Bleeding patterns will be recorded daily.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- You must be between 18-45 years old

- You have Heavy Periods

Exclusion Criteria:

- You are pregnant

- You are currently using hormonal contraception or hormonal therapy

- You have a history of pelvic inflammatory disease (and have not had a normal

pregnancy since)

- You had an infected abortion within the last three months

- You have abnormal or cancerous cells of the cervix or uterus

- You have an actine infection in your genital organs

- Known or suspected breast cancer

- Active liver disease or tumors

- Allergy to levonorgestrel or norethindrone

- You currently have deep vein thrombosis, pulmonary embolism, or history of these

conditions

- you currently have active or recent (within the past year) arterial thromboembolic

disease (such as a stroke or myocardial infarction) these conditions

Locations and Contacts

Wendy M White, CCRP, Phone: 254-724-8301, Email: wewhite@swmail.sw.org

Scott and White Hospital and Clinic, Temple, Texas 76508, United States; Recruiting
Wendy M White, CCRP, Phone: 254-724-8301, Email: wewhite@swmail.sw.org
Patricia J Sulak, MD, Principal Investigator
Additional Information

Starting date: January 2011
Last updated: July 7, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017